Furthermore, in another study [19], the authors found that the anti-tumour immunity caused by anti-PD-1 therapy was abrogated by chemotherapy when the latter was administered in a systemic way (intraperitoneal injection in their case), with decreased immune memory in long-term survivors. This evidence concerns the gene PDCD1 and neoplasm.